Development of novel antipsychotic drugs

Brain Research Reviews

Volumn 31, Issue 2-3, 2000, Pages 385-390

  Tallman, John F ^a  

^a NEUROGEN CORPORATION   (United States)

Author keywords

Antipsychotic drugs; Dopamine; Genomics; Schizophrenia; Serotonin

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; DOPAMINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SEROTONIN; SERTINDOLE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE;

BRAIN DEVELOPMENT; CONFERENCE PAPER; DRUG DESIGN; DRUG SCREENING; EXTRAPYRAMIDAL SYMPTOM; GENETICS; HUMAN; HYPOTENSION; HYPOTHESIS; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SEDATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; DRUG DESIGN; HUMANS; SCHIZOPHRENIA;

EID: 0034092989     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(99)00055-7     Document Type: Conference Paper

References (25)

1. S. Hirsch, D. Weinberger, Schizophrenia, Blackwell Science, Oxford, 1995.
2. R. Gur, Functional brain imaging studies in schizophrenia, in: F. Bloom, S. Kupfer (Eds.), Psychopharmacology, the fourth generation of progress, Raven Press, New York, 1995, pp. 1861-1874.
3. Weinberger D. On the plausibility of the neurodevelopmental hypothesis of schizophrenia. Neuropsychopharmacology. 14:1996;1S-12S.
4. Bertelsen A. Controversies and consistencies in psychiatric genetics. Acta Psychiat. Scand. 71:1985;61-75.
5. Weissman S.M. Genetic bases for common polygenic diseases. Proc. Natl. Acad. Sci. USA. 92:1995;8543-8544.
6. Lifton R.P. Molecular genetics of human blood pressure variation. Science. 272:1996;676-680.
7. Laborit H. Sur l'utilization de certain agents pharmacodynamiques a action neuro-vegetative en periode per- and post-operatioire. Acta Chir. Belg. 87:1949;485-492.
8. Carlsson A., Lindquist M. Effect of chlorpromazine and haloperidol on the formation of 3-methoxytyramine in mouse brain. Acta Pharmacol. 20:1963;140-144.
9. F.J. Monsma, O. Civelli, Dopamine receptors, in: M.J. Browne (Ed.), Recombinant cell surface receptors: focal point for therapeutic intervention, Landes, 1997, pp. 6-36.
10. Wess J. G-protein coupled receptors: molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J. 11:1997;346-354.
11. Tallman J.F., Primus R.J., Brodbeck R., Cornfield L., Meade R., Woodruff K., Ross P., Thurkauf A., Gallager D.W. NGD 94-1: Identification of a novel high affinity antagonist at the human dopamine D4 receptor. J. Pharm. Exp. Ther. 282:1997;1011-1019.
12. Meador-Woodruff J.H., Damask S.P., Wang J., Haroutunian V., Davis K.L., Watson S.J. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology. 15:1996;17-29.
13. Kramer M.S., Last B., Getson A., Reines S.A. The effects of a selective D4 dopamine receptor antagonist in acutely psychotic inpatients with schizophrenia. Arch. Gen. Psychiatry. 54:1997;567-572.
14. Barnes T.R.E., Gerlach J. D1 receptor antagonists in schizophrenia. Psychopharmacology. 121:1995;287-288.
15. J.D. Jentsch, J.D. Elsworth, J.R. Taylor, D.E. Redmond, R.H. Roth, Dysregulation of mesoprefrontal dopamine neurons induced by acute and repeated phencyclidine administration in the non human primate: implications for schizophrenia, Catecholamines: bridging basic science with clinical medicine, Adv. Pharmacol. 42, Academic Press, New York, 1998, pp. 810-813.
16. Kehne J.H., Baron B.M., Carr A.A.et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100907 as a potent 5-HT2a antagonist with a favorable CNS safety profile. J. Pharmacol. Exp. Ther. 277:1996;968-981.
17. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 281:1998;1349-1352.
18. Anonymous, 7Q11.23 deletions in Williams syndrome arise as a consequence of unequal meiotic crossover, Am. J. Hum. Genet. 54 (1996) 958-962.
19. Wang Y.K., Samos C.H., Peoples R., Jurado L.A., Nusse J., Francke U. A novel human homolog of the Drosophila frizzled wnt receptor gene binds wingless protein and is in the Williams syndrome deletion at 7q11.23. Hum. Mol. Genet. 6:1997;465-472.
20. Horuk R. Chemokines beyond inflammation. Nature. 393:1998;524-525.
21. Cho R.J., Fromont-Racine M., Wodicka C., Feuerbach B., Sterns L. Parallel analysis of genetic selections using whole genome oligonucleotide arrays. Proc. Nat. Acad. Sci. USA. 95:1997;3752-3757.
22. Cohen J. Developing prescriptions with a personal touch. Science. 275:1997;776.
23. Cohen J. The genomics gamble. Science. 275:1997;767-772.
24. Derisi J., Penlang L., Brown P., Bittner M.L., Meltzer P.S., Ray M., Chen Y., Su Y.A., Trent J.M. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nature Genetics. 14:1996;457-460.
25. Evans B.E., Rittle K.E., Bock M.G., DiPardo R.M., Friedinger R.M., Whitter W.L., Lundell G.F., Veber D.F., Anderson P.S., Chang R.S.L., Lotti V.J., Cerino D.J., Chen T.B., Kling P.J., Kunkel K.A., Springer J.P., Hirshfield J. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31:1988;2235-2246.